SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN
drugOn this page
Also known as Typhim viTyphoid vi polysaccharide vaccine
Summary
Salmonella Typhi Ty2 Vi Polysaccharide Antigen (CHEMBL5095389) is a phase-3 clinical-stage unknown; indicated across 3 conditions including typhoid fever and post-traumatic stress disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095389 |
| Name | SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN |
| Type | Unknown |
| Max phase | 3 |
Also known as: Typhim vi, Typhoid vi polysaccharide vaccine
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| typhoid fever | 1 | MONDO:0005619 | EFO:0006789 |
| post-traumatic stress disorder | 0 | MONDO:0005146 | EFO:0001358 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| EARLY_PHASE1 | 3 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT03312699 | PHASE1 | COMPLETED | Effects of Aging on Primary and Secondary Vaccine Responses |
| NCT03048929 | EARLY_PHASE1 | COMPLETED | Inflammation and Threat Sensitivity in PTSD |
| NCT03294564 | EARLY_PHASE1 | COMPLETED | Cognitive, Emotional, and Neural Responses to Acute Inflammation |
| NCT05346302 | EARLY_PHASE1 | COMPLETED | Persistent Readiness Through Early Prediction Immunization Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.